Ben Shepherd is a vascular biologist, tissue engineer and regenerative medicine scientist by training. He is also a board certified cardiovascular perfusionist. With over 10 years of experience in leading successful R&D teams and developing complex 3D human tissue systems, Ben is now the Co-founder and CEO at Trestle Biotherapeutics. Before co-founding Trestle, Ben served as VP of Research & Preclinical Development at Organovo, where he oversaw preclinical translational research. He led initial R&D efforts focused on use of 3D bioprinting for creation of in vitro tissue models for use in drug discovery, ADME/Tox, and disease modeling.

Ben received his BS in Zoology from the University of Washington, a PhD from the University of Arizona in Physiological Sciences, and conducted postdoctoral training at the Yale School of Medicine.